The Scandinavian Candesartan Acute Stroke Trial (SCAST) was a north European, multicentre, randomised, placebo-controlled, double-blind trial of candesartan in patients with acute stroke …

Results from the Scandinavian Candesartan Acute Stroke Trial (SCAST), presented by Eivind Berge, MD, Oslo University Hospital, Oslo, Norway, show no benefit and possibly some harm …

Mar 1, 2011 · The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 2011;377:741-750.

The Scandinavian Candesartan Acute Stroke Trial (SCAST) is designed to provide reliable data on the effects of candesartan in a wide variety of patients with acute stroke (target recruitment …

Feb 26, 2011 · Interpretation: There was no indication that careful blood-pressure lowering treatment with the angiotensin-receptor blocker candesartan is beneficial in patients with acute …

Feb 26, 2011 · report the results of the Scandinavian Candesartan Acute Stroke Trial (SCAST), in which they aimed to find out whether careful lowering of blood pressure, with the angiotensin …

Interpretation There was no indication that careful blood-pressure lowering treatment with the angiotensin-receptor blocker candesartan is beneficial in patients with acute stroke and raised …

Dive into the research topics of 'The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial'.

Welcome to the API Subcommittee on Aboveground Storage Tanks (SCAST) web page. SCAST provides an important service to the refining, marketing, pipeline and petrochemical industry …

SCAST was a randomized- and placebo-controlled, double-masked trial of the angiotensin receptor blocker candesartan in 2029 patients who presented within 30 hours of either an …